Physician profile
Carole E Thomas
NPI 1083666333
$76,740.13
in general payments reported to CMS, 2019-2025
48 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $12K · 2021: $9,905 · 2022: $594 · 2023: $386 · 2024: $373 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $72,190.63 | 2019-2021 | |
| Abbvie INC. | $660.98 | 2019-2025 | Qulipta, Botox, Ubrelvy |
| Validus Pharmaceuticals LLC | $467.25 | 2019-2021 | |
| Biogen, INC. | $410.69 | 2019-2023 | Plegridy, Vumerity, Avonex |
| Pfizer INC. | $324.92 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $258.95 | 2019-2020 | |
| Ucb, INC. | $228.00 | 2019-2024 | Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $223.93 | 2019-2024 | Austedo Xr, Austedo |
| Lilly USA, LLC | $203.24 | 2019-2025 | Kisunla |
| W. L. Gore & Associates, INC. | $183.84 | 2019-2025 | Gore Cardioform Septal Occluder |
| Alexion Pharmaceuticals, INC. | $163.56 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $98.54 | 2019-2020 | |
| Kyowa Kirin, INC. | $95.92 | 2020-2022 | |
| Adamas Pharmaceuticals, INC. | $85.91 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $83.23 | 2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carole Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.